Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: V-ATPase in glioma stem cells: a novel metabolic vulnerability

Fig. 1

V-ATPase inhibition in GSCs decreases glioma growth in vivo. a, b Luciferase-transduced GSCs treated with vehicle or 5 nM BafA1 for 24 h were intracranially injected in nude mice and glioma growth in vivo was evaluated by luciferase emission up to 144 days (BL Intensity; a,b). At sacrifice brains were collected and formalin-fixed and paraffine-embedded for morpho-histological examination. Then, a section was stained with STEM121, phosphorylated S6 at Serine 240/244 (pS6) and ki67 antibodies (brown color; c) to visualize respectively glioma cell infiltration in the brain parenchyma, cell growth and proliferation. STEM121, pS6 and ki67 staining was quantified using Image Scope (Leica) (j). Scale bar 1 mm left panel, 100 μm zoomed inset. Representative images are shown for A and C panels. **, p = 0.003 by Mann–Whitney U test

Back to article page